OncoMatch/Clinical Trials/NCT07108868
A Phase I Dose Finding Study of MB-CART2219.1
Is NCT07108868 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies CAR-T cells targeting CD19 and CD22 for lymphoma.
Treatment: CAR-T cells targeting CD19 and CD22 — A Phase I dose finding study of MB-CART2219.1 targeting CD19/CD22 in adult and pediatric patients with relapsed/refractory B-cell malignancies
Check if I qualifyExtracted eligibility criteria
Cancer type
Non-Hodgkin Lymphoma
Chronic Lymphocytic Leukemia
Acute Lymphoblastic Leukemia
Biomarker criteria
Required: CD19 expression (detected by flow cytometry or immunohistochemistry)
CD19 or CD22 expression must be detected on the malignant cells by flow cytometry or immunohistochemistry
Required: CD22 expression (detected by flow cytometry or immunohistochemistry)
CD19 or CD22 expression must be detected on the malignant cells by flow cytometry or immunohistochemistry
Performance status
ECOG 0–3(Limited self-care)
Prior therapy
Must have received: systemic therapy
after two or more systemic therapies, including one approved in label CAR-T-cell or bispecific antibody treatment option or with contraindications for such treatments
Must have received: BTK inhibitor
Patients with r/r CLL after established and approved treatment options including therapy with BTK inhibitors have failed
Lab requirements
Blood counts
Absolute neutrophil count (ANC) < 500/μL; Absolute lymphocyte count < 200/µL at time of leukapheresis; Platelet count < 50,000 mm3 (platelet transfusion allowed)
Kidney function
Serum Creatinine Clearance (CrCl) < 45 mL/min
Liver function
Serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2.5 × upper limit of normal (ULN); Serum total bilirubin > 1.5 × ULN or > 3.0 mg/dL for subjects with documented Gilbert's syndrome
Cardiac function
Echocardiogram (ECHO) or multi-gated acquisition (MUGA) with left ventricular ejection fraction < 45%
See Exclusion Criteria 5, 7
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify